HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• FDA’s ‘breakneck pace’ accelerates drug access, but concerns persist about lack of complete data
• Durvalumab extends PFS in advanced NSCLC
• ‘Explosive growth’ of interventional oncology prompts formation of new society
• Geneticist to lead Vanderbilt cancer center’s health disparities program
• Indo-American Cancer Association honors City of Hope researcher
• Oncology leaders: Biden Cancer Initiative will continue moonshot’s momentum
• OncoSec, Merck to collaborate on trial of ImmunoPulse IL-12, pembrolizumab in metastatic melanoma
• Ramucirumab improves PFS in advanced urothelial carcinoma
• Seattle Genetics halts trial of vadastuximab talirine for acute myeloid leukemia
• Supreme Court ruling on biosimilars ‘a win’ for patients
• The Wistar Institute appoints associate professor
• University of Alabama at Birmingham appoints cancer center director
• UT Health cancer center names director
• Emperors, gladiators and handmaidens Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Rituxan Hycela subcutaneous injection for blood cancers
• FDA expands approval of Zykadia for ALK–positive metastatic NSCLC
• FDA grants breakthrough therapy designation to GMI-1271 for AML
• FDA grants orphan drug designation to pIL-12 for unresectable melanoma
• FDA grants priority review to Keytruda for advanced gastric, gastroesophageal junction adenocarcinoma
• FDA rejects Coherus application for proposed biosimilar to Neulasta
• Alternative transfusion policy feasible for unknown blood types in emergency setting
• Inhaled corticosteroids may benefit patients with sickle cell disease
• Oral squamous cell carcinoma diagnosis affects sexual behavior
• Prostate cancer therapies show different rates of adoption
• Travel to academic centers improves pancreatic cancer survival
• CAR T-cell immunotherapy prompts durable response for ALL
• CAR T-cell therapy shows promise for patients with myeloma
• Childhood cancer survivors experience fewer severe health problems
• Low testosterone levels prevalent among testicular cancer survivors
• Momelotinib noninferior to ruxolitinib for spleen response in myelofibrosis
• Nivolumab shows promise for advanced cervical cancer
• Pembrolizumab reduces need for second-line therapy in advanced NSCLC
• Post-lumpectomy surgery rates for invasive breast cancer have declined
• Responses appear durable after completion of pembrolizumab therapy for melanoma
• Should an independent regulatory body oversee the FDA drug approval process?